{'52WeekChange': 0.08928573,
 'SandP52WeekChange': 0.0644362,
 'address1': '17 State Street',
 'address2': '7th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.32,
 'askSize': 4000,
 'averageDailyVolume10Day': 268800,
 'averageVolume': 374946,
 'averageVolume10days': 268800,
 'beta': 0.968627,
 'beta3Year': None,
 'bid': 1.22,
 'bidSize': 46000,
 'bookValue': 0.154,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.2632,
 'dayLow': 1.22,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.827,
 'enterpriseToRevenue': None,
 'enterpriseValue': 124313320,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.3287143,
 'fiftyTwoWeekHigh': 2.04,
 'fiftyTwoWeekLow': 0.86,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 56176130,
 'forwardEps': -0.2,
 'forwardPE': -6.1,
 'fromCurrency': None,
 'fullTimeEmployees': 18,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.55581003,
 'heldPercentInstitutions': 0.1176,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1585612800,
 'lastMarket': None,
 'lastSplitDate': 1411689600,
 'lastSplitFactor': '4:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/tymeinc.com',
 'longBusinessSummary': 'Tyme Technologies, Inc., a clinical-stage '
                        'biotechnology company, develops cancer '
                        'metabolism-based therapies (CMBTs) in the United '
                        'States. Its lead candidate is the SM-88, a CMBT that '
                        'is in a Phase II/III clinical trial to treat across '
                        '15 types of cancer, including pancreatic, lung, '
                        'breast, prostate, sarcoma, and lymphoma. The company '
                        'also offers TYME-18, a CMBT compound that is in '
                        'preclinical stage for the treatment of solid tumors. '
                        'Tyme Technologies, Inc. has a research collaboration '
                        'with NYU Langone Health to advance the development of '
                        'treatments for patients with metastatic cancers, '
                        'including pancreatic cancer, as well as with Mayo '
                        'Clinic; and a strategic collaboration with Eagle '
                        'Pharmaceuticals, Inc. to advance oral SM-88 for the '
                        'treatment of patients with cancer. The company was '
                        'formerly known as Global Group Enterprises Corp. Tyme '
                        'Technologies, Inc. was founded in 2011 and is '
                        'headquartered in New York, New York.',
 'longName': 'Tyme Technologies, Inc.',
 'market': 'us_market',
 'marketCap': 154464208,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_288228332',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -22000556,
 'nextFiscalYearEnd': 1648684800,
 'open': 1.24,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '212 461 2315',
 'previousClose': 1.23,
 'priceHint': 4,
 'priceToBook': 7.922078,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.2632,
 'regularMarketDayLow': 1.22,
 'regularMarketOpen': 1.24,
 'regularMarketPreviousClose': 1.23,
 'regularMarketPrice': 1.24,
 'regularMarketVolume': 354939,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 126610000,
 'sharesPercentSharesOut': 0.0343,
 'sharesShort': 4317497,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4454628,
 'shortName': 'Tyme Technologies, Inc.',
 'shortPercentOfFloat': 0.0588,
 'shortRatio': 11.11,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'TYME',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.192,
 'twoHundredDayAverage': 1.339741,
 'volume': 354939,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.tymeinc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10004'}